frexalimab + brivekimig + rilzabrutinib + placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Focal Segmental Glomerulosclerosis
Conditions
Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Trial Timeline
Dec 19, 2024 → Feb 16, 2028
NCT ID
NCT06500702About frexalimab + brivekimig + rilzabrutinib + placebo
frexalimab + brivekimig + rilzabrutinib + placebo is a phase 2 stage product being developed by Sanofi for Focal Segmental Glomerulosclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06500702. Target conditions include Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06500702 | Phase 2 | Recruiting |
Competing Products
20 competing products in Focal Segmental Glomerulosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OnabotulinumtoxinA 145 UNT [Botox] | AbbVie | Approved | 85 |
| Dapagliflozin | AstraZeneca | Approved | 85 |
| Enfuvirtide + Tenofovir-Emtricitabine | Roche | Phase 2 | 52 |
| CCX140-B | Amgen | Phase 2 | 51 |
| PF-06730512 | Pfizer | Phase 2 | 51 |
| Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide | Pfizer | Approved | 84 |
| VX-147 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-147 | Vertex Pharmaceuticals | Phase 1 | 32 |
| IXP | Vertex Pharmaceuticals | Phase 1 | 32 |
| fresolimumab + fresolimumab + Placebo | Sanofi | Phase 2 | 51 |
| GC1008 + GC1008 + GC1008 + GC1008 | Sanofi | Phase 1 | 32 |
| Vivaglobin | CSL | Phase 2 | 51 |
| UCB0942 | UCB | Phase 2 | 49 |
| Levetiracetam + Carbamazepine + Lamotrigine | UCB | Approved | 82 |
| Brivaracetam + Brivaracetam | UCB | Phase 2 | 49 |
| Lacosamide | UCB | Phase 2 | 49 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 49 |
| Lacosamide | UCB | Pre-clinical | 20 |
| ARGX-117 | Argenx | Phase 2 | 49 |
| Empasiprubart + IVIG (Intravenous Immunoglobulin) | Argenx | Phase 3 | 74 |